Substance / Medication

Antazoline

Overview

Active Ingredient
antazoline
RxNorm CUI
865

Indications

INDICATION AND USAGE : Nestabs® One is a prescription prenatal multi-vitamin/mineral supplement with DHA that can be taken throughout pregnancy and during the postnatal period for both lactating and non-lactating mothers.Nestabs® One may also be useful in improving the nutritional status of women prior to conception. The usual dose is one softgel daily, or as directed by a physician.

Labeler: Womens Choice Pharmaceuticals, LLCUpdated: 2025-04-28T00:00:00.000ZFull label on DailyMed

Boxed Warning

FDA Black Box Warning

WARNING KEEP THIS PRODUCT OUT OF THE REACH OF CHILDREN : Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age.. In case of accidental overdose, call a doctor or poison control center immediately

Contraindications

When this intervention should not be used

CONTRAINDICATIONS : This product is contraindicated in patients with a known hypersensitivity to any of theingredients.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

1 trials linked to this intervention

1
Total Trials
0
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Green and blue space exposure and non-communicable disease related hospitalizations: A systematic review.
Luque-García L, Muxika-Legorburu J, Mendia-Berasategui O et al. · Environ Res · 2024
PMID: 38157973Meta-Analysis
Respiratory dysfunction in degenerative cervical myelopathy: A systematic review.
Elliott Lorcan, Li Michael, Gharooni Aref-Ali et al. · J Clin Neurosci · 2024
PMID: 38237493Meta-Analysis
Respiratory dysfunction in persistent somatic symptoms: A systematic review of observational studies.
Niwa Saya, Fila-Pawłowska Karolina, Van den Bergh Omer et al. · J Psychosom Res · 2024
PMID: 38388305Meta-Analysis
Validity and reliability of outcome measures to assess dysfunctional breathing: a systematic review.
Mohan Vikram, Rathinam Chandrasekar, Yates Derick et al. · BMJ Open Respir Res · 2024
PMID: 38626928Meta-AnalysisFull text (PMC)
A comprehensive meta-analysis on safety outcomes reveals the novel potentials of SGLT2is, especially preventing respiratory diseases.
Cai YuJun, Zou HaiTao, Hu Rong et al. · Front Endocrinol (Lausanne) · 2024
PMID: 38742192Meta-AnalysisFull text (PMC)
A Systematic Literature Review of the Natural History of Respiratory, Swallowing, Feeding, and Speech Functions in Spinal Muscular Atrophy (SMA).
Martí Yasmina, Aponte Ribero Valerie, Batson Sarah et al. · J Neuromuscul Dis · 2024
PMID: 38943396Meta-AnalysisFull text (PMC)
Exposure to outdoor particulate matter and risk of respiratory diseases: a systematic review and meta-analysis.
Nakhjirgan Pegah, Kashani Homa, Kermani Majid · Environ Geochem Health · 2023
PMID: 38153542Meta-Analysis
Efficacy and safety of antazoline vs propafenone for conversion of paroxysmal atrial fibrillation to sinus rhythm: a randomized, double-blind study (AnProAF).
Karwowski Jarosław, Wrzosek Karol, Mączyńska-Mazuruk Renata et al. · Pol Arch Intern Med · 2024
PMID: 38166357RCT
Efficacy and safety of antazoline in the rapid cardioversion of paroxysmal atrial fibrillation (the AnPAF Study).
Maciag Aleksander, Farkowski Michal M, Chwyczko Tomasz et al. · Europace · 2017
PMID: 28339554RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Antazoline (substance)
SNOMED CT
373544004
UMLS CUI
C0003143
RxNorm CUI
865
Labeler
Womens Choice Pharmaceuticals, LLC

Clinical Data

This intervention maps to 3 entities in the Ltrl knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
1
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.